NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune  (ITMN) has led the biotech sector higher.

Roche will pay $74 a share for InterMune, which represents a 38% premium to Friday's closing price of $53.80, in an all-cash deal.

Ariad was up 6.43% to $6.62 at 12:35 p.m. More than 8.3 million shares had changed hands to edge the average volume of 8,129,760.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ARIA data by YCharts

Image placeholder title

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.